The common acute lymphoblastic leukemia antigen (CALLA, CDIO), which is expressed on early lymphoid progenitors and neutrophils, is the zinc metalloprotease, neutral endopeptidase 24.11 (NEP, "enkephalinase"). The CDlO cell surface enzyme is known to hydrolyze a variety of biologically active peptides including met-enkephalin, formyl-met-leu-phe (f-MLP), and substance P. These three CDlO/NEP substrates induce the migration and aggregation of neutrophils, suggesting that each of the peptides can function as a mediator of neutrophil inflammatory responses. Recently, inhibition of CDlO/NEP was found to reduce the concentration of metenkephalin needed to activate human and invertebrate granulocytes by several orders of magnitude. Herein we show HE CDlO CELL surface glycoprotein, which was origi-T nally identified as a tumor-associated antigen on acute lymphoblastic leukemias (common acute lymphoblastic leukemia antigen, CALLA),'f2 is also expressed on normal lymphoid progenitors3 and neutrophils: CDlO expression is restricted to early lymphoid ontogeny and terminal myeloid differentiation, suggesting that the protein functions during discrete stages of hematopoietic development. The predicted amino acid sequence of the CDlO cDNA is virtually identical to that of the zinc metalloprotease neutral endopeptidase 24.11 (NEP, "enkephalina~e").~" Furthermore, introduction of a transcriptionally active CDlO gene into a CD10-cell line results in cell surface neutral endopeptidase enzymatic activity.6 CDlO/NEP hydrolyzes a variety of naturally occurring peptides, including the endogenous opioid pentapeptides met-and leu-enkephalin.' In recent studies, met-enkephalin has been shown to induce morphologic changes, and directed migration and aggregation of both invertebrate hemocytes and human neutrophils?" Inhibition of CD10/ NEP enzymatic activity reduces the amount of metenkephalin required to trigger changes in the shape and size of these cells by several orders of magnitude." Therefore, the neuropeptide met-enkephalin also functions as an inflammatory mediator and cell surface CDlO/NEP regulates met-enkephalin associated inflammatory responses by 
HE CDlO CELL surface glycoprotein, which was origi-T nally identified as a tumor-associated antigen on acute lymphoblastic leukemias (common acute lymphoblastic leukemia antigen, CALLA),'f2 is also expressed on normal lymphoid progenitors3 and neutrophils: CDlO expression is restricted to early lymphoid ontogeny and terminal myeloid differentiation, suggesting that the protein functions during discrete stages of hematopoietic development. The predicted amino acid sequence of the CDlO cDNA is virtually identical to that of the zinc metalloprotease neutral endopeptidase 24.11 (NEP, "enkephalina~e").~" Furthermore, introduction of a transcriptionally active CDlO gene into a CD10-cell line results in cell surface neutral endopeptidase enzymatic activity. 6 CDlO/NEP hydrolyzes a variety of naturally occurring peptides, including the endogenous opioid pentapeptides met-and leu-enkephalin. ' In recent studies, met-enkephalin has been shown to induce morphologic changes, and directed migration and aggregation of both invertebrate hemocytes and human neutrophils?" Inhibition of CD10/ NEP enzymatic activity reduces the amount of metenkephalin required to trigger changes in the shape and size of these cells by several orders of magnitude." Therefore, the neuropeptide met-enkephalin also functions as an inflammatory mediator and cell surface CDlO/NEP regulates met-enkephalin associated inflammatory responses by controlling local concentrations of the peptide." For these reasons, the identification of two additional CDlO/NEP substrates, f-met-leu-phe (f-MLP)12 and substance P,13 as inflammatory mediators is of particular interest. The tripeptide f-MLP is the major chemotactic peptide produced by gram-negative bacterial4 and the tachykinin substance P is a primary mediator of neurogenic inflammation of the respiratory tract." Stimulation of afferent nerves in the bronchial mucosa triggers local substance P release, which induces bronchospasm, cough, increased vascular permeability, and migration of neutrophils into an affected area." By analogy with its effect on met-enkephalin induced inflammation, CDlO/NEP may also affect f-MLP-and substance-Passociated changes in neutrophil morphology and migration and influence inflammatory peptide-mediated modulation of neutrophil adhesion molecules.
Neutrophils activated with a variety of physiologic stimuli, including f-MLP, undergo coordinated changes in the expression of the adhesion proteins Mol (CDllb/CD18) and LAM-l.I6-l9 Mol (CDllb/CDlS) is a member of the leukocyte integrin family and the cell surface receptor for the complement cleavage product C3bLzo LAM-12' (TQ-l,= Leu8:' LECAM-1) is the human homologue of murine gplOOMELI4, which mediates lymphocyte and neutrophil adhesion to specialized high-endothelial venules.w26 Neutrophils adhere to the vascular endothelium adjacent to an inflammatory site and become activated by chemotactic factors released from the area of inflammation. On activation, neutrophils shed cell surface LAM-1 and express increased cell surface Mol; these changes may facilitate neutrophil extravasation and migration into an area of inflammation.'*^^^ To further explore the role of CDlO/NEP in regulating neutrophil inflammatory responses, we have stimulated neutrophils with f-MLP and substance P after pharmacologic inhibition of CDlO/NEP and evaluated resulting changes in cell morphology, migration, and Mol and LAM-1 expression. As earlier studies indicated that neutrophil CDlO/NEP was internalized after antigenic modulation2' or phorbol ester treatment:' we have also evaluated the effects of neutrophil activation on cell surface CD10/
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NEP enzymatic activity using a variety of physiologic stimuli.
MATERIALS AND METHODS
Reagents. f-MLP, phorbol myristate acetate (PMA), A23187, phosphoramidon, and thiorphan were purchased from Sigma Chemical Co (St Louis, MO) and met-enkephalin and substance P were purchased from Peninsula Laboratories (Belmont, CA). Captopril was a gift from L. Hersh (University of Texas Southwestern Medical Center, Dallas) and recombinant granulocytemacrophage colony-stimulating factor (GM-CSF) was a gift of S. Clark and G. Wong (Genetics Institute, Cambridge, MA). Recombinant tumor necrosis factor (TNF) was obtained from Asahi Chemical Corp (Shikuoza, Japan). Media (RPMI 1640; GIBCO, Gaithersburg, MD) containing less than 0.03 endotoxin U/mL and sterile plastic pipettes, test tubes, and flasks were used in all experiments to avoid endotoxin contamination.
Sources of human cells. Heparinized human blood was obtained from volunteer donors after informed consent. In certain experiments, peripheral blood was separated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient centrifugation and peripheral blood granulocytes were isolated from Ficoll pellets by dextran ~edimentation~~ and resuspended in RPMI without additions for further analysis.
Analysis of neutrophils by light microscopy, Purified neutrophils were resuspended at 1 x 106/mL in RPMI and stimulated with the indicated concentration of f-MLP or substance P with or without phosphoramidon (100 kmol/L). Cell suspensions were then added to a coverslip precoated with 2% bovine albumin, placed on a slide, and analyzed at 20°C by time-lapse video recording as previously described.'" The changes in shape and area of individual cells were analyzed at 5-minute intervals for 15 minutes using phase contrast and Nomarski optics on a Zeiss Axiophot microscope (Carl Zeiss, Inc, Thomwood, NY).'" Analysis of neutrophil chemotaxis. Purified neutrophils were washed twice with Gey's balanced salt solution (GBSS) with 2% bovine serum albumin (BSA) and subsequently resuspended at 4 x lo6 cells/mL in GBSS/O.Z% BSA alone or GBSS/02% BSA supplemented with 10 pmol/L thiorphan, or captopril. Neutrophils were subsequently evaluated for chemotaxis toward the indicated concentrations of f-MLP or substance P using a 48-well chemotaxis chamber containing a polycarbonate filter with S-pmol/L pores (Neuroprobe, Calvin John, MD) as previously de~cribed.'~~" All assays were performed in duplicate using 2 X l@ neutrophils/well. After a 60-minute incubation at 37"C, cells on the upper surface of the filter were removed and cells on the lower filter surface were fixed in methanol and stained with Diff-Quick (Baxter Health Care, Miami, FL).31 Cells migrating through the filter in response to f-MLP, substance P, or no addition, with or without thiorphan or captopril pretreatment, were subsequently counted (see Fig 2  legend ). Five representative high-power fields per sample were analyzed. Net migration was determined by substracting the number of thiorphan-or captopril-treated cells that migrated in the absence of a specific stimulus (see Fig 2 legend ) from the number of thiorphan-or captopril-treated cells that migrated in response to a specific chemotactic stimulus (f-MLP or substance P). As indicated (see Fig 2 legend ), the migration of untreated, thiorphan-treated, and captopril-treated neutrophils in the absence of a specific chemotactic stimulus was similar.
Aliquots of heparinized whole blood or purified peripheral blood granulocytes were incubated at 22°C for 15 minutes with phosphoramidon, thiorphan, or captopril(l0 or 100 p,mol/L). Cell samples were then stimulated with either f-MLP or substance P at the indicated Cell culture and immunofluorescence analysis.
concentrations or TNF (100 U/mL), GM-CSF (10 ng/mL), or A23187 (5 x lo-' mol/L) and incubated thereafter at 37°C for the indicated time periods (30 minutes unless specified).
Aliquots of each sample were phenotyped with a panel of monoclonal antibodies (MoAbs) with the following specificities: 1D3, a neutrophil-specific epitope of CD16 (J.D.G., unpublished data, 1988); anti-T11, (3T4-8B5), an epitope of the T-cell CD2 antigen3'; anti-MY4, the monocyte-specific epitope of the CD14 antigen"; 904, the Mol or CDllb adhesion proteinM; and TQ-1, the human homologue of murine gp10OMEL1' (LAM-1''*26). In all experiments, a class-matched IgGl MoAb 3Cll directed against a secreted protein (y-interferon), was used as a negative control. Phenotyping was performed as previously described.%'* Briefly, cell samples were incubated with primary antibody for 25 minutes at 4"C, washed, and incubated with fluoresceinated goat antimouse Ig (Whittaker M.A. Bioproducts, Walkersville, MD) for a similar time period. Thereafter, the erythrocytes in whole blood samples were lysed and the remaining cells fixed using the Coulter Immunology whole blood lysis kit (Coulter Immunology, Hialeah, FL). Fluorescence analysis was performed using a Coulter Epics 753 cell sorter and neutrophils were identified using a combination of right angle and forward angle light scatter and reactivity with neutrophilspecific antibodies. Mean channel fluorescence was determined for each sample using a log scale and log channel fluorescence units were converted to linear channel fluorescence units to facilitate comparison of Mol and LAM-1 between samples. The relationship between log and linear channel fluorescence units was determined by simultaneously analyzing calibrated fluorescent beads on both log and linear scales and plotting the results on semi-log paper (linear fluorescence, y-axis; log fluorescence, x-axis). The resulting fixed relationship between log and linear channel fluorescence values allowed conversion of a given log channel fluorescence value (x-axis) to the corresponding linear channel fluorescence value (y-axis). The percentage changes in Mol and LAM-1 fluorescence in given test samples were determined by comparing the Mol and LAM-1 linear channel fluorescence of test samples with that of untreated controls. Nonspecific fluorescence, which was detected using the negative control antibody 3Cl1, was similar in test samples and untreated controls. In analyses of Mol and LAM-1 modulation, whole blood samples were stimulated, phenotyped, and processed as noted previously to avoid activation of neutrophils during the purification procedure.
Purified neutrophils that were untreated or stimulated with PMA, f-MLP, TNF, GM-CSF, or A23187 in RPMI without additives were analyzed for CDlO/NEP enzymatic activity at indicated time intervals with a sensitive fluorimetric assay using glutaryl-ala-ala-phe-4-methoxy-2-napthylamide as a substrate.6
Enzymatic assays. 1-MLP or substance P (plus or minus phosphoramidon) with that of untreated controls. The changes in shape and area of individual cells were analyzed a t 5-minute intervals for 15 minutes using phase contrast and Normarski optics on a Zeiss Axiophot microscope with a Zelss vldeoplant/Video image analysis system. F* cells were evaluated for each f-MLP or substance P f phosphoramidon combination. Results are displayed as mean f standard deviation. The observed differences in cell area of untreated and phosphoramidon-treated neutrophils were evaluated uslng a one-sided Student's t-test: f-MLP lo-@, P = not significant (NS); 1-MLP 10-'9 P < .05; 1-MLP lo-", P < .Owl; substance P P = NS; substance P lo-', P < .01; substance P lo-', P = NS.
RESULTS
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meters have lower ff values. In the presence of phosphoramidon, the minimum concentration of f-MLP required to trigger neutrophil morphologic changes and increases in cell area was reduced by three orders of magnitude, from lo-* mol/L to lo-" mol/L (Fig 1A) . Neutrophils stimulated with f-MLP lo-" mol/L alone retained their rounded inactive shape (ff = .85 k .017), whereas cells preincubated with phosphoramidon before f-MLP (lo-" mol/L) stimulation had decreased peripheral refractility and increased in cell area by -35% (ff = .44 k .031, P < .001). Phosphoramidon alone had no effect on neutrophil size and shape (ff = .87 f .020).
In analogous experiments, neutrophils were stimulated with the indicated concentrations of substance P in the presence or absence of phosphoramidon (Fig 1B) . Inhibition of CDlO/NEP also reduced the concentration of substance P required to trigger changes in neutrophil morphology.
Neutrophil chemotaxis toward f-MLP and substance P is increased after CDl OINEP inhibition. The above-mentioned changes in neutrophil morphology precede directed migration along an f-MLP or substance P concentration gradient. To directly assess CDlO/NEP effects on f-MLPor substance-P-mediated chemotaxis, neutrophil migration was evaluated after inhibition of cell surface CDlO/NEP with the CDlO/NEP inhibitor, thiorphan (N-[DL-2-benzyl-3-mercaptopropionyl]gly~ine).~~ As a control, cells were also preincubated with captopril (D-3-mercapto-2-methyl propanoyl-L-proline), which has a structure similar to that of thiorphan but is inactive against CDlO/NEP." Net migration was determined by subtracting the number of thiorphan-or captopril-treated cells that migrated in the absence of a specific stimulus from the number of thiorphan-or captopril-treated cells that migrated in response to a specific chemotactic stimulus (f-MLP or substance P). As indicated in Fig 2, migration toward Fig  3A) . However, neutrophils preincubated with phosphoramidon before stimulation with f-MLP to lo-'' mol/L expressed -55% more Mol and 20% less LAM-1 than cells with the intact metalloprotease ( Fig 3A) . Neutrophils preincubated with the unrelated CDlO/NEP inhibitor, thiorphan, also had increased modulation of adhesion proteins after stimulation with reduced doses of f-MLP. For example, thiorphan-treated neutrophils expressed 35% more Mol than either untreated or captopril-treated neutrophils (Table 1) . These results are consistent with those obtained in assays of neutrophil morphology and migration (Figs 1  and 2 ), which suggest that at limiting concentrations of f-MLP the stimulatory effects of the peptide are influenced by cell surface CDlO/NEP enzymatic activity. Substance P also modulated neutrophil cell surface adhesion molecule expression. As indicated in Fig 3B, neutrophils stimulated with substance P (lo-' mol/L) expressed -150% more Mol and -20% less LAM-1 than untreated cells. Furthermore, the inhibition of CDlO/NEP with phosphoramidon potentiated the effects of reduced doses of substance P in a manner analogous to that for f-MLP (Fig 3) . Ncutrophils with intact CDlO/NEP did not undcrgo substantial changcs in Mol or LAM-1 cxprcssion aftcr stimulation with substancc P lo-'' mol/L; in contrast, ncutrophils prctrcatcd with phosphoramidon bcforc sub-
Mol and -25% lcss LAM-1, rcspcctivcly (Fig 3R) . Nerttrop/ril activation affects cell nrrface CDIOINEP enzymatic activiy. Thc studics dcscribcd previously indicatc that pharmacologic inhibition of CDlO/NEP rapidly potcntiatcs thc cffccts of inflammatory pcptidcs that arc CDlOI NEP substratcs. Rcccnt rcports indicatc that ncutrophils stimulatcd with cithcr phorbol myristatc acctatc or a diacylglyccrol analoguc intcrnalizc thc majority of thcir ccll surfacc CDlO/NEP within 5 to 30 minutcs.-'x Thcrcforc, ncutrophil ccll surfacc CDlO/NEP may bc rcgulatcd by thc activation statc of thc ccll during thc timc pcriod in which thc cnzymc has its most pronounced cffccts. To furthcr cxplorc thc rclationship bctwccn activation and CDlO/ NEP cnzymatic activity (Fig S) , ncutrophils use only.
For personal at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From from peripheral blood, stimulated for 5 to 30 minutes with the direct protein kinase C activator PMA, the calcium ionophore A23187, f-MLP, or the cytokines TNF or GM-CSF. Samples were subsequently analyzed for cell surface CDlO/NEP enzymatic activity (Fig 5, top panel) and for Mol and LAM-1 expression as a parameter of neutrophil activation (Fig 5, middle and lower panels) . As previously described,B neutrophils stimulated with PMA rapidly lost CDlO/NEP enzymatic activity as they underwent changes in cell surface adhesion molecule expression. Thus, neutrophils stimulated with PMA for 30 minutes had -60% less functional CDlO/NEP than cells incubated for the same time period without PMA and 47% less enzymatic activity than untreated cells at time zero (Fig 5) . To determine whether CDlO downregulation is a general consequence of neutrophil activation via protein kinase C, cells were stimulated with f-MLP or TNF, which also signal through this kinase p a t h~a y . '~,~~ In contrast to the results obtained with PMA, neutrophils treated with either f-MLP or TNF had increased CDlO/NEP enzymatic activity after activation (Fig 5) . Furthermore, cells treated with the protein kinase C independent stimulator GM-CSF or the calcium ionophore A23187 also had increased CDlO/NEP enzymatic activity (Fig 5) . In all cases, neutrophil activation resulted in increased Mol and decreased LAM-1 expression (Fig 5) . Collectively, these results suggest that not all activators of neutrophils reduce cell surface CDlO enzymatic activity and that there is a dynamic relationship between neutrophil activation and CDlO/NEP activity. Inflammatory mediators such as f-MLP, TNF, and GM-CSF may influence neutrophil sensitivity to CDlO/NEP substrates by affecting the degradation of these substrates via CDlO/NEP.
DISCUSSION
Our analysis of neutrophil activation and CDlO/NEP activity leads to several conclusions. First, CDlO/NEP substrates that mediate neutrophil inflammatory responses induce coordinated changes in cell morphology, migration, and expression of the cell surface adhesion proteins. Second, the degree of activation associated with these CDlO/NEP substrates is influenced by cell surface CD10/ NEP enzymatic activity. Third, CDlO/NEP enzymatic activity is also endogenously regulated by the activation state of the cell.
Several lines of evidence suggest that inflammatory peptide-mediated changes in neutrophil adherence and migration are potentiated by the inhibition of CDlO/NEP. In our earlier in vitro studies, the concentration of metenkephalin required to induce changes in neutrophil size and shape was reduced by several orders of magnitude after CDlO/NEP inhibition." The current studies show that less f-MLP or substance P was needed to trigger changes in neutrophil morphology and migration after abrogation of CDlO/NEP enzymatic activity. These biologic effects may, in part, be explained by the increased modulation of neutrophil cell surface adhesion proteins that occurs when neutrophils are stimulated with CDlO substrates after inhibition of the enzyme. The in vivo consequences of CDlO/NEP inhibition on inflammation are only now becoming evident. For example, in one rat model of substance-Pinduced neurogenic inflammation, increased numbers of neutrophils adhered to venules and increased numbers of adherent neutrophils migrated out of venules into the surrounding tracheal mucosa after CDlO/NEP inhibit i~n . '~'~~ Neutrophil CDlO/NEP appears to have a more important regulatory role under conditions in which the concentrations of stimulatory peptides are limited" (Figs 1 through  3) . Our results (Fig 1) are consistent with earlier studies in which high-dose f-MLP induced changes in neutrophil shape that were unaffected by CDlO/NEP inhibition.'* More importantly, our studies expand on these earlier observations by demonstrating that inhibition of CD10/ NEP potentiates the effects of low-dose f-MLP and substance P without significantly altering the effects of highdose peptides. These results are consistent with the notion that a degradative enzyme is more likely to have physiologic effects when its target substrate is in limited supply.
Our earlier studies'' and this report suggest that CD10/ NEP regulates local concentrations of inflammatory peptides and, in so doing, affects resultant inflammatory responses. These data suggest that CDlO/NEP inhibition increases the effective concentration of certain inflammatory peptides by several orders of magnitude. A recent report of phosphoramidon decreasing neutrophil chemotaxis toward an optimal f-MLP gradientI2 may reflect the fact that CDlO/NEP inhibition increases the effective f-MLP concentration to a supraoptimal range associated with reduced inflammatory responses. Neutrophils stimulated with optimal met-enkephalin concentrations after phosphoramidon preincubation have similar reduced inflammatory responses.'' Inflammatory responses result from the concerted action of cytokines and peptides released by multiple cell types. These inflammatory mediators directly activate target cells but also augment the release of additional cytokines and peptides and affect the sensitivity of target cells to further stimulation. For example, substance P stimulates monocytes to secrete cytokines including interleukin-1 (IL-l), TNF, and 1L-6a; similarly, met-enkephalin, which is produced by activated T cells,"' triggers monocytes>2 These results raise the possibility that CDlO/NEP substrates may stimulate neutrophils through both direct and indirect mechanisms. However, modulation of neutrophil morphology and adhesion proteins occurs within minutes of CDlO/ NEP substrate addition, whereas monocyte activation by substance P or met-enkephalin requires several hours of stimulation.""' Furthermore, f-MLP, substance P, and met-enkephalin trigger rapid changes in the size and shape of purified neutrophils, indicating that CDlO/NEP substrates, themselves, have direct effects on these cells.
Recent studies suggest that certain inflammatov mediators control resulting biologic effects by downregulating neutrophil cell surface cytokine receptors.43 Our data indicate that an additional means of regulating an ongoing inflammatory response is modulation of neutrophil CD10/ NEP. The rapid internalization of neutrophil CDlO/NEP use only.
For personal at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From that occurs after phorbol ester stimulation is similar to that which results from specific antibody treatment of CD10' cells." It is possible that neutrophils stimulated with PMA have increased f-MLP binding, in part, because PMA reduces CDlO/NEP enzymatic activity.@ It is not yet known why Ph4A downregulates neutrophil cell surface CD10/ NEP enzymatic activity while other stimuli such as GM-CSF, TNF, f-MLP, and calcium ionophores are associated with increased enzymatic activity. Presumably, CDlO/NEP regulation may involve protein kinase C-mediated intemalization of the enzyme as well as other processes such as enzyme mobilization from intracellular stores, and modulation of CDlO/NEP transcription and/or mRNA stability. In any event, the dynamic relationship between neutrophil activation and cell surface CDlO/NEP enzymatic activity suggests that the enzyme has an important role in regulating neutrophil responsiveness to multiple inflammatory peptides.
